Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 17, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 20, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001635088-26-000026
Filed / recorded
Mar 20, 2026, 2:36 AM UTC
Added to OQRO
Oct 6, 2026, 8:46 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Roivant Sciences Ltd.
Issuer CIK
1635088
Ticker
ROIV
Reporting person
Eric Venker
Relationship
Officer
Officer title
President & Immunovant CEO
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Mar 17, 2026
Transaction code
M
Shares / units
200,000
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
4,844,834
Ownership form
Direct
Amendment
No
Footnotes from the filing
Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).